CAPZA1抗体;CAPZA1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11621(CAPZA1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P11621(CAPZA1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The CAPZA1 antibody targets the CAPZA1 protein, a key component of the capping protein complex that regulates actin filament dynamics. CAPZA1 (Capping Actin Protein of Muscle Z-Line Alpha Subunit 1) forms a heterodimer with CAPZB, binding to the fast-growing (barbed) ends of actin filaments to stabilize them and control elongation. This activity is critical for maintaining cytoskeletal architecture, cell motility, and intracellular trafficking. CAPZA1 is ubiquitously expressed, with roles in diverse processes, including neuronal development, immune response, and cancer metastasis. Dysregulation of CAPZA1 has been linked to pathologies such as neurodegenerative disorders and tumor invasion.

Antibodies against CAPZA1 are widely used in research to investigate its expression, localization, and function. They enable techniques like Western blotting, immunofluorescence, and immunohistochemistry, helping to map CAPZA1 distribution in tissues or cultured cells. Some studies employ these antibodies to explore CAPZA1's interaction with other cytoskeletal proteins or its phosphorylation status under signaling stimuli. Commercially available CAPZA1 antibodies are typically raised in hosts like rabbits or mice, with validation across specific applications. Researchers prioritize antibodies with high specificity and low cross-reactivity to avoid off-target effects, especially given structural similarities among capping protein family members. Reliable CAPZA1 antibodies are essential tools for dissecting actin-related mechanisms in health and disease.